

Abstract

The composition of the present invention comprises a sodium channel blocking compound which is capable of specifically binding to a site, either on an SS1 region or an SS2 region, on an extracellular region of a sodium channel alpha subunit, and a
5 pharmaceutically acceptable carrier.